Session

IBD (Posters)

HEAD-TO-HEAD PHARMACOKINETIC ANALYSIS OF INFLIXIMAB MONO- VS COMBINATION THERAPY IN PAEDIATRIC CROHN’S DISEASE
HEAD-TO-HEAD PHARMACOKINETIC ANALYSIS OF INFLIXIMAB MONO- VS COMBINATION THERAPY IN PAEDIATRIC CROHN’S DISEASE

HOW IS THE CLINICAL COURSE AND DRUG TOXICITY IN LATE-ONSET IBD PATIENTS?
HOW IS THE CLINICAL COURSE AND DRUG TOXICITY IN LATE-ONSET IBD PATIENTS?

THE PERSISTENCE OF ANTI-SPIKE ANTIBODIES FOLLOWING TWO SARS-COV-2 VACCINES IN PATIENTS WITH INFLAMMATORY BOWEL- AND JOINT DISEASES ON IMMUNOSUPPRESSIVE THERAPY COMPARED TO HEALTHY CONTROLS – A PROSPECTIVE COHORT STUDY
THE PERSISTENCE OF ANTI-SPIKE ANTIBODIES FOLLOWING TWO SARS-COV-2 VACCINES IN PATIENTS WITH INFLAMMATORY BOWEL- AND JOINT DISEASES ON IMMUNOSUPPRESSIVE THERAPY COMPARED TO HEALTHY CONTROLS – A PROSPECTIVE COHORT STUDY

SAFETY OF COVID-19 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA OF A NATIONAL STUDY (ESCAPE-IBD)
SAFETY OF COVID-19 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA OF A NATIONAL STUDY (ESCAPE-IBD)

SMOKING AND COLITIS-ASSOCIATED COLORECTAL NEOPLASIA: EXPLORING THE RELATIONSHIP
SMOKING AND COLITIS-ASSOCIATED COLORECTAL NEOPLASIA: EXPLORING THE RELATIONSHIP

MUCOSAL AND PLASMA METABOLOMES IN NEW-ONSET PAEDIATRIC INFLAMMATORY BOWEL DISEASE: CORRELATIONS WITH DISEASE CHARACTERISTICS AND PLASMA INFLAMMATION PROTEIN MARKERS
MUCOSAL AND PLASMA METABOLOMES IN NEW-ONSET PAEDIATRIC INFLAMMATORY BOWEL DISEASE: CORRELATIONS WITH DISEASE CHARACTERISTICS AND PLASMA INFLAMMATION PROTEIN MARKERS

USTEKINUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE: RESULTS UP TO WEEK 104 OF THE STARDUST TRIAL
USTEKINUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE: RESULTS UP TO WEEK 104 OF THE STARDUST TRIAL

RELATIONSHIP BETWEEN INTESTINAL ULTRASOUND, FECAL CALPROTECTIN AND HARVEY BRADSHAW INDEX IN THE ASSESSMENT OF INFLAMMATORY ACTIVITY IN CROHN'S DISEASE
RELATIONSHIP BETWEEN INTESTINAL ULTRASOUND, FECAL CALPROTECTIN AND HARVEY BRADSHAW INDEX IN THE ASSESSMENT OF INFLAMMATORY ACTIVITY IN CROHN'S DISEASE

HIDRADENITIS SUPPURATIVA AND INFLAMMATORY BOWEL DISEASE IN A CASE-CONTROL STUDY
HIDRADENITIS SUPPURATIVA AND INFLAMMATORY BOWEL DISEASE IN A CASE-CONTROL STUDY

EXCLUSIVE ENTERAL NUTRITION DRIVES PROTECTIVE MICROBIOME MODULATION IN PEDIATRIC CROHN’S DISEASE
EXCLUSIVE ENTERAL NUTRITION DRIVES PROTECTIVE MICROBIOME MODULATION IN PEDIATRIC CROHN’S DISEASE

ENDOSCOPIC FEATURES OF NON-IBD COLITIS
ENDOSCOPIC FEATURES OF NON-IBD COLITIS

METAGENOMIC ANALYSIS OF A SIGNATURE GUT MICROBIOME BIOMARKER IN CROHN'S DISEASE ACROSS FIVE POPULATIONS
METAGENOMIC ANALYSIS OF A SIGNATURE GUT MICROBIOME BIOMARKER IN CROHN'S DISEASE ACROSS FIVE POPULATIONS

ANTI-INFLAMMATORY AND BARRIER STABILIZING EFFECTS OF A HERBAL COMBINATION MEDICINE OF MYRRH, COFFEE CHARCOAL AND CHAMOMILE FLOWER EXTRACT IN A MULTI-COMPONENT CELL MODEL OF THE INFLAMED INTESTINAL MUCOSA
ANTI-INFLAMMATORY AND BARRIER STABILIZING EFFECTS OF A HERBAL COMBINATION MEDICINE OF MYRRH, COFFEE CHARCOAL AND CHAMOMILE FLOWER EXTRACT IN A MULTI-COMPONENT CELL MODEL OF THE INFLAMED INTESTINAL MUCOSA

DEFINITIVE SURGICAL MANAGEMENT OF PERIANAL FISTULAS IN ADULTS WITH CROHN’S DISEASE: A CROSS-SECTIONAL ANALYSIS OF LOCAL PRACTICE IN AUSTRALIA AND NEW ZEALAND
DEFINITIVE SURGICAL MANAGEMENT OF PERIANAL FISTULAS IN ADULTS WITH CROHN’S DISEASE: A CROSS-SECTIONAL ANALYSIS OF LOCAL PRACTICE IN AUSTRALIA AND NEW ZEALAND

EFFECTIVENESS AND SAFETY OF SWITCHING FROM ADALIMUMAB REFERENCE TO BIOSIMILAR IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: THE ADA-SWITCH STUDY
EFFECTIVENESS AND SAFETY OF SWITCHING FROM ADALIMUMAB REFERENCE TO BIOSIMILAR IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: THE ADA-SWITCH STUDY

ENDOSCOPIC SCORES AS PREDICTORS OF TREATMENT FAILURE IN ULCERATIVE COLITIS
ENDOSCOPIC SCORES AS PREDICTORS OF TREATMENT FAILURE IN ULCERATIVE COLITIS

EXPLORATORY ANALYSIS OF FILGOTINIB SAFETY DATA IN A SELECTED POPULATION OF PATIENTS WITH RHEUMATOID ARTHRITIS: DATA FROM FINCH 1–4 AND DARWIN 1–3 STUDIES IN PERSPECTIVE TO INTEGRATED ULCERATIVE COLITIS SAFETY DATA
EXPLORATORY ANALYSIS OF FILGOTINIB SAFETY DATA IN A SELECTED POPULATION OF PATIENTS WITH RHEUMATOID ARTHRITIS: DATA FROM FINCH 1–4 AND DARWIN 1–3 STUDIES IN PERSPECTIVE TO INTEGRATED ULCERATIVE COLITIS SAFETY DATA

INFLUENCE OF DIABETES MELLITUS ON INFLAMMATORY BOWEL DISEASE COURSE AND TREATMENT OUTCOMES.A SYSTEMATIC REVIEW WITH META-ANALYSIS
INFLUENCE OF DIABETES MELLITUS ON INFLAMMATORY BOWEL DISEASE COURSE AND TREATMENT OUTCOMES.A SYSTEMATIC REVIEW WITH META-ANALYSIS

LOW FREQUENCIES OF CIRCULATING INHIBITORY TIGIT+CD38+ EFFECTOR T CELLS IDENTIFY AN IMMUNOLOGICALLY DISTINCT SUBGROUP OF PEDIATRIC PATIENTS WITH SEVERE CROHN’S DISEASE
LOW FREQUENCIES OF CIRCULATING INHIBITORY TIGIT+CD38+ EFFECTOR T CELLS IDENTIFY AN IMMUNOLOGICALLY DISTINCT SUBGROUP OF PEDIATRIC PATIENTS WITH SEVERE CROHN’S DISEASE

INCREASE IN CIRCULATING T AND B LYMPHOCYTE SUBSETS AFTER TREATMENT WITH THE POTENT, SELECTIVE, ORAL, SMALL MOLECULE ALPHA4BETA-7 INHIBITOR MORF-057 IN HEALTHY SUBJECTS
INCREASE IN CIRCULATING T AND B LYMPHOCYTE SUBSETS AFTER TREATMENT WITH THE POTENT, SELECTIVE, ORAL, SMALL MOLECULE ALPHA4BETA-7 INHIBITOR MORF-057 IN HEALTHY SUBJECTS

Item 201 - 220 / 612
1 2 3 4 5 6 7 8 9 10
11
12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31